EA200401241A1 - Форма для введения, включающая неустойчивое в кислой среде действующее вещество, единица действующего вещества, способ ее получения и микросфера - Google Patents
Форма для введения, включающая неустойчивое в кислой среде действующее вещество, единица действующего вещества, способ ее получения и микросфераInfo
- Publication number
- EA200401241A1 EA200401241A1 EA200401241A EA200401241A EA200401241A1 EA 200401241 A1 EA200401241 A1 EA 200401241A1 EA 200401241 A EA200401241 A EA 200401241A EA 200401241 A EA200401241 A EA 200401241A EA 200401241 A1 EA200401241 A1 EA 200401241A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- active substance
- substance
- microsphere
- introduction
- obtaining
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 6
- 230000002378 acidificating effect Effects 0.000 title abstract 2
- 239000004005 microsphere Substances 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000012188 paraffin wax Substances 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
В заявке описаны новые формы для введения и препараты неустойчивых в кислой среде действующих веществ. Новые формы для введения включают отдельные единицы действующего вещества, при этом действующее вещество присутствует в виде отдельных единиц действующего вещества в матрице, которая включает смесь по меньшей мере одного триглицерида и по меньшей мере одного твердого парафина, или в матрице, которая включает смесь по меньшей мере одного эфира жирной кислоты и по меньшей мере одного твердого парафина. В частности, единицы действующего вещества имеют форму микросфер, которые могут быть получены грануляцией разбрызгиванием.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99110865 | 1999-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200401241A1 true EA200401241A1 (ru) | 2005-02-24 |
EA006899B1 EA006899B1 (ru) | 2006-04-28 |
Family
ID=8238296
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200401241A EA006899B1 (ru) | 1999-06-07 | 2000-05-31 | Форма для введения, включающая неустойчивое в кислой среде действующее вещество, единица действующего вещества, способ ее получения и микросфера |
EA200101266A EA005803B1 (ru) | 1999-06-07 | 2000-05-31 | Новый препарат и форма для введения, включающие неустойчивое в кислой среде действующее вещество |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200101266A EA005803B1 (ru) | 1999-06-07 | 2000-05-31 | Новый препарат и форма для введения, включающие неустойчивое в кислой среде действующее вещество |
Country Status (31)
Country | Link |
---|---|
US (3) | US7794752B1 (ru) |
EP (2) | EP1616562A1 (ru) |
JP (1) | JP4980527B2 (ru) |
KR (1) | KR100833633B1 (ru) |
CN (1) | CN1361683A (ru) |
AT (1) | ATE300285T1 (ru) |
AU (1) | AU775995B2 (ru) |
BG (1) | BG106165A (ru) |
BR (1) | BR0011347A (ru) |
CA (1) | CA2376202C (ru) |
CZ (1) | CZ20014405A3 (ru) |
DE (1) | DE60021570T2 (ru) |
DK (1) | DK1187601T3 (ru) |
EA (2) | EA006899B1 (ru) |
EE (1) | EE200100660A (ru) |
ES (1) | ES2246238T3 (ru) |
HK (1) | HK1046643A1 (ru) |
HR (1) | HRP20020006A2 (ru) |
HU (1) | HUP0201637A3 (ru) |
IL (2) | IL146504A0 (ru) |
MX (1) | MXPA01012659A (ru) |
NO (1) | NO20015980L (ru) |
PL (1) | PL352882A1 (ru) |
PT (1) | PT1187601E (ru) |
SI (1) | SI1187601T1 (ru) |
SK (1) | SK285247B6 (ru) |
TR (1) | TR200103527T2 (ru) |
UA (1) | UA74339C2 (ru) |
WO (1) | WO2000074654A1 (ru) |
YU (1) | YU86001A (ru) |
ZA (1) | ZA200110000B (ru) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE0100823D0 (sv) * | 2001-03-09 | 2001-03-09 | Astrazeneca Ab | Method I to obtain microparticles |
UA80393C2 (ru) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице |
CA2430816C (en) | 2000-12-07 | 2012-05-15 | Altana Pharma Ag | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
JP2004514737A (ja) | 2000-12-07 | 2004-05-20 | アルタナ ファルマ アクチエンゲゼルシャフト | 酸分解性活性成分を含有する迅速に崩壊する錠剤 |
WO2002045692A1 (en) * | 2000-12-07 | 2002-06-13 | Altana Pharma Ag | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
JP4310605B2 (ja) | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
ME00524B (me) | 2003-03-10 | 2011-10-10 | Astrazeneca Ab | Novi postupak za dobijanje roflumilasta |
TW200503783A (en) * | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
PE20050150A1 (es) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
CL2004000983A1 (es) | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
WO2005074898A2 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori |
US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
WO2006097456A1 (en) | 2005-03-16 | 2006-09-21 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
US7884208B2 (en) | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
AR061348A1 (es) | 2006-06-12 | 2008-08-20 | Teva Pharma | Preparados estables de laquinimod |
US20090318403A1 (en) * | 2006-08-03 | 2009-12-24 | Prosensa Technologies B.V. | Antibiotic composition |
CN103349659A (zh) * | 2006-09-26 | 2013-10-16 | 塔罗制药北美有限公司 | 液体药物组合物以及应用 |
DK2234485T3 (da) | 2007-12-20 | 2014-02-10 | Teva Pharma | Stabile laquinimod-præparater |
KR101094231B1 (ko) | 2008-02-18 | 2011-12-14 | 하나제약 주식회사 | 서방성 고형 제제 및 그의 제조방법 |
CA2719246A1 (en) * | 2008-03-26 | 2009-10-01 | Taro Pharmaceuticals North America, Inc. | Stabilizing lipid compositions for oral pharmaceutical agents |
WO2010018593A2 (en) * | 2008-07-03 | 2010-02-18 | Torrent Pharmaceuticals Ltd. | Gastric acid resistant benzimidazole multiple unit tablet composition |
AU2009288108B2 (en) | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
KR101107609B1 (ko) * | 2009-09-21 | 2012-01-25 | 주식회사 한양비이에스티교육 | 태양에너지 발전 및 응용 교육을 위한 보트형 학습교재 |
EP2338477A1 (en) | 2009-12-15 | 2011-06-29 | bene-Arzneimittel GmbH | Suppository comprising pantoprazole |
EA025377B1 (ru) | 2010-07-09 | 2016-12-30 | Тева Фармасьютикал Индастриз Лтд. | Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение |
WO2012171540A1 (en) | 2011-06-15 | 2012-12-20 | Bene-Arzneimittel Gmbh | Suppository comprising pantoprazole comprised in pellets with a cellulose core |
EP3225617A1 (en) | 2012-02-16 | 2017-10-04 | Teva Pharmaceutical Industries Ltd | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
WO2014074381A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
NZ720512A (en) * | 2013-11-13 | 2018-01-26 | Tillotts Pharma Ag | Multi-particulate drug delivery system |
CN107412171B (zh) * | 2017-04-21 | 2020-04-17 | 湖南赛隆药业有限公司 | 注射用左旋泮托拉唑钠长效微球冻干制剂及其制备方法 |
CN107007561B (zh) * | 2017-04-21 | 2019-12-03 | 湖南赛隆药业有限公司 | 一种左旋泮托拉唑钠缓释微球及其制备方法 |
WO2019161175A1 (en) | 2018-02-15 | 2019-08-22 | Boston Scientific Scimed, Inc. | Introducer with expandable capabilities |
WO2020172629A1 (en) * | 2019-02-21 | 2020-08-27 | ChromaDex Inc. | Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE27C (de) * | 1877-08-02 | GRAHL und HÖHL zu Dresden | Akkumulator zum Betriebe von Hutpressen | |
US3065142A (en) | 1958-07-30 | 1962-11-20 | Armour Pharma | Gastric resistant medicinal preparation |
US3800038A (en) | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
DE2725924C3 (de) * | 1977-06-08 | 1980-11-06 | Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau | Verfahren zur Herstellung kugelförmiger Teilchen aus niedrigschmelzenden organischen Substanzen |
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
EP0031134B1 (en) | 1979-12-19 | 1984-07-18 | Goudsche Machinefabriek B.V. | Continuously working crystallizer |
JPS58116471A (ja) | 1981-12-29 | 1983-07-11 | Nippon Kayaku Co Ltd | 4−ヒドロキシメチル−1−フタラゾンエステル誘導体およびその塩 |
US4637966A (en) * | 1983-10-21 | 1987-01-20 | Gates Energy Products, Inc. | Sealed lead-acid cell |
US4876094A (en) * | 1984-01-13 | 1989-10-24 | Battelle Development Corporation | Controlled release liquid dosage formulation |
JPS60248618A (ja) * | 1984-05-24 | 1985-12-09 | Nippon Zoki Pharmaceut Co Ltd | ジペプチドを含有する潰瘍治療剤 |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
JO1406B1 (en) | 1984-11-02 | 1986-11-30 | سميث كلاين اند فرينش لابوراتوريز ليمتد | Chemical compounds |
DE3524572A1 (de) * | 1985-07-10 | 1987-01-15 | Thomae Gmbh Dr K | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung |
ES2032394T3 (es) * | 1986-02-20 | 1993-02-16 | Hoechst Aktiengesellschaft | Procedimiento para preparar derivados de tienoimidazol sustituidos. |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
CA1256109A (en) * | 1986-09-10 | 1989-06-20 | Franz Rovenszky | Process for the preparation of derivatives of 4, 5-dihydrooxazoles |
FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
JP2681373B2 (ja) | 1988-07-18 | 1997-11-26 | 塩野義製薬株式会社 | 徐放性製剤の製造法 |
ES2057338T3 (es) | 1989-11-29 | 1994-10-16 | Toa Eiyo Ltd | Derivados de cicloheptenopiridina, procedimiento para su preparacion y agentes antiulcerosos que los contienen. |
FR2657257B1 (fr) * | 1990-01-19 | 1994-09-02 | Rhone Poulenc Sante | Procede de preparation de medicaments sous forme de perles. |
US5213810A (en) * | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
DE4018642C2 (de) | 1990-06-11 | 1993-11-25 | Byk Gulden Lomberg Chem Fab | Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes |
DE4022648C2 (de) * | 1990-07-17 | 1994-01-27 | Nukem Gmbh | Verfahren und Vorrichtung zur Herstellung von kugelförmigen Teilchen aus flüssiger Phase |
TW209174B (ru) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
KR0141909B1 (ko) * | 1991-11-08 | 1998-06-15 | 보조 다꾸로 | 액정 표시 디바이스 제조 방법 |
JP2973751B2 (ja) * | 1991-12-04 | 1999-11-08 | 大正製薬株式会社 | 矯味経口組成物の製造方法 |
TW272942B (ru) * | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
FR2707184B1 (fr) * | 1993-07-08 | 1995-08-11 | Rhone Poulenc Nutrition Animal | Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique. |
EP0995447A1 (en) * | 1993-09-09 | 2000-04-26 | Takeda Chemical Industries, Ltd. | Formulation comprising antibacterial substance and antiulcer substance |
NL9400618A (nl) | 1994-04-18 | 1995-12-01 | Goudsche Machinefabriek Bv | Inrichting voor het koelen en verwerken van een gesmolten produkt tot een granulaatprodukt. |
SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
UA41946C2 (ru) | 1994-07-08 | 2001-10-15 | Астра Актієболаг | Пероральная фармацевтическая составная лекарственная форма в виде таблетки, способ ее получения, упаковка в виде блистера и способ ингибирования секреции желудочной кислоты и/или лечения желудочно-кишечных воспалительных заболеваний |
SE512835C2 (sv) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
FR2754177B1 (fr) | 1996-10-07 | 1999-08-06 | Sanofi Sa | Microspheres pharmaceutiques d'acide valproique pour administration orale |
JP2001503766A (ja) * | 1996-11-12 | 2001-03-21 | フアーマシア・アンド・アツプジヨン・アー・ベー | 複数の多孔質セルロースマトリクス(pcm)を含むコンパクト部材、その製造および使用方法 |
GB9710800D0 (en) | 1997-05-23 | 1997-07-23 | Cipla Limited | Pharmaceutical composition and method of preparing it |
ID20812A (id) * | 1997-07-09 | 1999-03-11 | Takeda Chemical Industries Ltd | Senyawa polyol, produk dan penggunaannya |
WO1999007342A1 (en) * | 1997-08-11 | 1999-02-18 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
ATE500815T1 (de) * | 1997-12-08 | 2011-03-15 | Dietrich Rango | Neue suppositoriumsform mit säureempfindlichem wirkstoff |
NL1007904C2 (nl) | 1997-12-24 | 1999-06-25 | Goudsche Machinefabriek Bv | Werkwijze en inrichting voor het vormen van granulaat uit een smelt van chemische producten. |
DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
HUP0101248A2 (hu) * | 1998-03-20 | 2001-08-28 | Kowa Co., Ltd. | Gyomor- és/vagy nyombél-adhezív gyógyászati készítmények |
US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
JP4370429B2 (ja) | 1998-09-10 | 2009-11-25 | 東和薬品株式会社 | 徐放性マイクロスフエアの製造法 |
DE19848849A1 (de) | 1998-10-22 | 2000-04-27 | Knoll Ag | Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz |
-
2000
- 2000-05-31 AT AT00935151T patent/ATE300285T1/de not_active IP Right Cessation
- 2000-05-31 PT PT00935151T patent/PT1187601E/pt unknown
- 2000-05-31 WO PCT/EP2000/004958 patent/WO2000074654A1/en active IP Right Grant
- 2000-05-31 BR BR0011347-6A patent/BR0011347A/pt not_active Application Discontinuation
- 2000-05-31 HU HU0201637A patent/HUP0201637A3/hu unknown
- 2000-05-31 MX MXPA01012659A patent/MXPA01012659A/es active IP Right Grant
- 2000-05-31 JP JP2001501191A patent/JP4980527B2/ja not_active Expired - Fee Related
- 2000-05-31 EE EEP200100660A patent/EE200100660A/xx unknown
- 2000-05-31 US US09/980,492 patent/US7794752B1/en not_active Expired - Fee Related
- 2000-05-31 ES ES00935151T patent/ES2246238T3/es not_active Expired - Lifetime
- 2000-05-31 SI SI200030755T patent/SI1187601T1/sl unknown
- 2000-05-31 EP EP05104345A patent/EP1616562A1/en not_active Withdrawn
- 2000-05-31 TR TR2001/03527T patent/TR200103527T2/xx unknown
- 2000-05-31 UA UA2002010191A patent/UA74339C2/ru unknown
- 2000-05-31 IL IL14650400A patent/IL146504A0/xx active IP Right Grant
- 2000-05-31 EA EA200401241A patent/EA006899B1/ru not_active IP Right Cessation
- 2000-05-31 DE DE60021570T patent/DE60021570T2/de not_active Expired - Lifetime
- 2000-05-31 SK SK1802-2001A patent/SK285247B6/sk not_active IP Right Cessation
- 2000-05-31 PL PL00352882A patent/PL352882A1/xx unknown
- 2000-05-31 EP EP00935151A patent/EP1187601B1/en not_active Expired - Lifetime
- 2000-05-31 CA CA002376202A patent/CA2376202C/en not_active Expired - Fee Related
- 2000-05-31 AU AU50741/00A patent/AU775995B2/en not_active Ceased
- 2000-05-31 EA EA200101266A patent/EA005803B1/ru not_active IP Right Cessation
- 2000-05-31 DK DK00935151T patent/DK1187601T3/da active
- 2000-05-31 KR KR1020017015776A patent/KR100833633B1/ko not_active IP Right Cessation
- 2000-05-31 CN CN00808668A patent/CN1361683A/zh active Pending
- 2000-05-31 YU YU86001A patent/YU86001A/sh unknown
- 2000-05-31 CZ CZ20014405A patent/CZ20014405A3/cs unknown
-
2001
- 2001-11-14 IL IL146504A patent/IL146504A/en not_active IP Right Cessation
- 2001-12-03 BG BG06165A patent/BG106165A/bg unknown
- 2001-12-05 ZA ZA200110000A patent/ZA200110000B/xx unknown
- 2001-12-06 NO NO20015980A patent/NO20015980L/no not_active Application Discontinuation
-
2002
- 2002-01-04 HR HR20020006A patent/HRP20020006A2/hr not_active Application Discontinuation
- 2002-11-18 HK HK02108341.7A patent/HK1046643A1/zh unknown
-
2006
- 2006-02-09 US US11/349,969 patent/US7790198B2/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/980,572 patent/US7785630B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200401241A1 (ru) | Форма для введения, включающая неустойчивое в кислой среде действующее вещество, единица действующего вещества, способ ее получения и микросфера | |
EA200300634A1 (ru) | Фармацевтическая композиция, содержащая действующее вещество, диспергированное в матрице | |
FR2855823B1 (fr) | Nouveaux composes de type ceramide, leur procede de synthese, et compositions cosmetiques et/ou pharmaceutiques en contenant | |
DE60022664D1 (de) | Herstellungsverfahren von submikrometerwirkstoffpartikeln | |
IS2354B (is) | Lyfjasamsetning sem mögulegt er að hleypa | |
GEP20064022B (en) | Pharmaceutical formulations comprising oxycodone and naloxone | |
MY138975A (en) | Novel preparation and administration form comprising an acid-labile active compound | |
TNSN91047A1 (fr) | Forme galenique injectable retardee | |
DE3862337D1 (de) | Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten. | |
YU17899A (sh) | Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu | |
MY143793A (en) | Non-tabletted, chewable, individually dosed administration forms | |
BRPI0407652A (pt) | método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição | |
Dittert et al. | Acetaminophen prodrugs II: Effect of structure and enzyme source on enzymatic and nonenzymatic hydrolysis of carbonate esters | |
WO2001070993A3 (en) | Polynucleotides that control delta-6-desaturase genes and methods for identifying compounds for modulating delta-6-desaturase | |
IT1292126B1 (it) | Esteri cerosi arricchiti in acidi grassi omega-3 insaturi,loro preparazione ed uso | |
EA200200211A1 (ru) | Фармацевтическая композиция и ее приготовление | |
NL185454C (nl) | Esterderivaat van een anti-inflammatoir werkzaam carbonzuur, werkwijze voor het bereiden daarvan en farmaceutisch preparaat met anti-inflammatoire werking. | |
BR9603766A (pt) | Preparação inseticida líquida para fumigação a quente processo para matar insetos por fumigação a quente e uso de um éster isopropílico de ácido graxo superior ou de ftalato de dibutila como agente anti-entupimento | |
AR014093A1 (es) | Una molecula de acido nucleico aislado, una proteina aislada de pulga, una composicion terapeutica, su uso, metodo para producir laproteina, metodo in vitro para identificar un compuesto capaz de inhibir la actividad de la proteasa de la pulga y la actividad de | |
EP1046337A3 (de) | Wasserbasierte Formulierungen mit fungizider Wirkung | |
TH50963A (th) | สารผสมแอสคอร์บิลฟอสเฟตสำหรับเพิ่มอัตราการต่ออายุเซลล์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title |